REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
1 hedge funds and large institutions have $1K invested in REGENERX BIOPHARMACEUTICALS in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
80% less capital invested
Capital invested by funds: $5K → $1K (-$4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$3K |
RGN Hedge Fund Activity: Q3 2022 in Review
1 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q3 2022, worth a combined $1K — down 80% from $5K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RGN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was MAI Capital Management, exiting entirely with an estimated $3K sold.
- 1 institutional investor held REGENERX BIOPHARMACEUTICALS (RGN) as of Q3 2022, down from 2 in Q2 2022.
- Funds reported $1K of REGENERX BIOPHARMACEUTICALS stock for Q3 2022, down 80% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q3 2022 and 1 closed out, a net change of -1 holder.
- The largest REGENERX BIOPHARMACEUTICALS seller in Q3 2022 was MAI Capital Management, an estimated $3K sold.
Based on aggregated 13F filings for Q3 2022.